UFL1

E3 UFM1-protein ligase 1 · O94874 · UFL1 on Sugi Atlas →

0 patent compounds predicted against UFL1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to UFL1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults PHASE3WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection PHASE2WITHDRAWN
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients PHASE2WITHDRAWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Studying TAK-243 in Patients With Advanced Cancer PHASE1RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas nanRECRUITING
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome nanCOMPLETED
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 nanRECRUITING
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
HRQoL and Financial Toxicity in Patients With VEXAS Syndrome nanRECRUITING
Male breAsT cAncer preDisposition Factor: Creation of a Control Cohort 2 nanNOT_YET_RECRUITING
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC) nanUNKNOWN
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome nanRECRUITING
Role of USP35 in the Detection of Ferroptosis in Juvenile Autoimmune Hepatitis nanNOT_YET_RECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS nanRECRUITING
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure nanCOMPLETED
PREVENT ALL ALS Study nanRECRUITING
Establishment of a Prospective Clinical-biological Database nanRECRUITING
Cell Signaling, Reinnervation and Metabolism in Kennedy Disease and Amyotrophic Lateral Sclerosis (ALS) nanUNKNOWN
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a UFL1 binder may also engage these)

ProteinNameSimilarity
A1A4I9 1.000 A1A4I9 →
Q4R367 1.000 Q4R367 →
Q8CCJ3 1.000 Q8CCJ3 →
B2GV24 1.000 B2GV24 →
Q5ZMG1 0.998 Q5ZMG1 →
Q6PGY6 0.996 Q6PGY6 →
Q9DBA9 0.987 Q9DBA9 →
Q66HC5 0.984 Q66HC5 →
Q5ZL91 0.983 Q5ZL91 →
Q9BPX3 0.983 Q9BPX3 →
Q9NVH2 0.983 Q9NVH2 →
Q7TQK1 0.983 Q7TQK1 →
A5PJZ5 0.983 A5PJZ5 →
P32780 0.982 P32780 →
Q9H9C1 0.982 Q9H9C1 →
Q8BJ71 0.981 Q8BJ71 →
Q6P3X3 0.981 Q6P3X3 →
P37199 0.981 P37199 →
F4IDS7 0.981 F4IDS7 →
P97878 0.980 P97878 →
Q9XHM1 0.980 Q9XHM1 →
Q6DDM4 0.980 Q6DDM4 →
Q1RMS6 0.980 Q1RMS6 →
Q9YHB5 0.980 Q9YHB5 →
Q14CX7 0.980 Q14CX7 →
Q00004 0.980 Q00004 →
NUP155 Nuclear pore complex protein Nup155 0.979 landscape →
F4HQ84 0.979 F4HQ84 →
Q7ZX96 0.979 Q7ZX96 →
A5D796 0.979 A5D796 →